Clinical trial Recruiting at 1 site Observational Ages 18 and up

Non-Invasive Heart Failure Monitoring in Hospitalized Patients

Official title: Hemodynamic Observational Study in Patients With Heart Failure Using a Non-Invasive Multi-Modal Sensing Device (HOSP-HF)

Run by Acorai AB · NCT07671742 · Data updated 2026-11-12

This study tests whether daily non-invasive thoracic measurements from the Acorai Device 1.0 can relate to health outcomes for adults hospitalized with heart failure.

More Heart Failure trials

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment1000 (estimated)
SponsorAcorai AB
Industry-sponsored
Locations1 site (Lund)
StatusRecruiting
StartedApril 1, 2026
Main results expectedMarch 1, 2027
Study endsApril 1, 2027
Registry record updatedJune 26, 2026
Trial IDNCT07671742 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults (18+) hospitalized for primary heart failure with congestion requiring therapy, able to consent.

Probably not a fit

Patients who do not experience heart failure-related readmission or mortality within 90 days or whose health status does not correlate with the device measurements may see no direct benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective, multicenter observational study follows adults admitted with heart failure to see how non-invasive thoracic sensor data from the Acorai Device 1.0 relate to clinical data and outcomes. Participants have daily five-minute recordings during hospitalization and are tracked for 90 days after discharge for heart failure hospitalization or death. The device records multimodal signals without altering clinical care or management. Researchers will compare sensor measurements with demographics, vitals, labs, imaging, and outcomes to identify potential associations. No diagnostic or therapeutic procedures are introduced by the study and data are collected from medical records where available.

Why it matters

Potential benefit: If associations are found, the device could help clinicians understand congestion and hemodynamics with less burden on patients.

How similar studies have gone: Previous non-invasive hemodynamic sensing in heart failure has shown informative signals, but this study adds prospective, daily in-hospital monitoring to assess predictive associations.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age ≥18 years
* Hospitalization for primary heart failure, defined as new or worsening heart failure symptoms with objective evidence of congestion requiring initiation or intensification of heart failure-specific therapy
* Ability to provide written informed consent

Exclusion Criteria:

* Any discretionary exclusion where the inclusion of the subject is deemed to pose potential risks to the subject's well-being or is likely to comprise the compliant performance of the study.
* Pregnancy or lactation (as confirmed by self-report or medical documentation)
* Presence of a skin rash or open wound in the area where the Acorai Device model 1.0 will be applied
* Any other condition that, in the opinion of the investigator, would preclude the subject from participating in the study or may affect the integrity of the data

Where it's running

  • Skåne University Hospital
    Lund, Sweden
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.